Pfizer Aktie News

Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff.

Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III ...

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.

These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.

Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning....

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation.

Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.